Data security in pharma marketing—the path to maturity

Data security in pharma marketing—the path to maturity

What brand managers need to know to achieve data security maturity

Blockbuster Drug Boycott? What ESI's Sovaldi Threat Means to Big Pharma

Blockbuster Drug Boycott? What ESI's Sovaldi Threat Means to Big Pharma

Express Scripts warned of building an anti-Sovaldi coalition. If payers are unwilling to pay for such drugs, or band against their makers, where does pharma go from here?

Marketing in the Modern Attention Economy: 9 "M-Words" Modern CMOs Should Consider

Marketing in the Modern Attention Economy: 9 "M-Words" Modern CMOs Should Consider

Nine things CMOs should consider when desiring to engage consumers who no longer want to give their attention to boring and scripted product descriptions.

Gens X, Y and diabetes: Not as invincible as they think?

Gens X, Y and diabetes: Not as invincible as they think?

Are today's young adults on their way to healthier lives in middle age and beyond? New data from GfK's Roper Diabetes study series gives cause for concern.

A Message About Messages

A Message About Messages

More credit ought to be given to the investments and inventions made by the biopharmaceutical sector—no question. But placing responsibility on the media for a perceived lack of fairness seems misplaced.

Surging Enrollment—Has the Affordable Care Act Turned a Corner?

Surging Enrollment—Has the Affordable Care Act Turned a Corner?

With enrollment having just reached five million in a push to the March 31 deadline, the ACA is poised to turn the corner of public opinion.

SXSW: Key takeaways for healthcare marketers

SXSW: Key takeaways for healthcare marketers

Why I left SXSW this past week feeling like I just might live forever

How social business is transforming healthcare

How social business is transforming healthcare

Healthcare companies are partnering with social entrepreneurs to drive their own agendas on affordability and access while staying at the forefront of global initiatives

Five things big pharma can learn from the rare-disease community

Five things big pharma can learn from the rare-disease community

Incentives aren't the only reason orphan drugs are a success. More important are the lessons companies have learned about patients, social media and support.

Unraveling the real story in the data trail: people

Unraveling the real story in the data trail: people

Being decoded helps harness technology to bring out the best in people, attract talent and, ultimately, improve customer service, say authors of a new book

Three major med-tech trends to watch

Three major med-tech trends to watch

A rundown of the big trends in devices & diagnostics in 2014, based on research and analysis, and the growth opportunities they will provide

Supermarket(ing)

Supermarket(ing)

What it would be like to advertise treatment for earwax impaction, hypersalivation and gas during the big game.

Not everything about Healthcare.gov is bad

Not everything about Healthcare.gov is bad

Looking past all the noise, beleaguered portal offers pointed lessons to healthcare website developers

Wearable, shareable and seamless technology

Wearable, shareable and seamless technology

Looking beyond the plethora of fitness trackers on display at CES 2014, one can glean which consumer trends are likely to impact the future of pharma marketing—Are you ready for the Internet of Things?

When Sales Force Met Marketing

When Sales Force Met Marketing

For this romance between two unlikely partners to work, Pharma must let go of its idea of a traditional sales force.

Should pharma be social? Patients respond

Should pharma be social? Patients respond

A patient panel provides a prescription for pharma social media success

Seizing the MoCial trend

Seizing the MoCial trend

How pharma can integrate mobile & social in 2014

Stop using the term "patient-centric"—and other rules for the New Pharma Value Proposition

Stop using the term "patient-centric"—and other rules for the New Pharma Value Proposition

Fundamental flaws in our current business model must be fixed if our industry is to stay vital and competitive into the next decade.

Closing the digital intelligence gap

Closing the digital intelligence gap

Getting to an integrated mar-comms model isn't easy. Addressing your agency's lack of digital skills is a good start.

Reasons to believe

Reasons to believe

All decisions have an emotional component. Even those, like technology, where we think reason has won the day.

DTC ads should do more than raise eyebrows

DTC ads should do more than raise eyebrows

The ad push around "Low T," and ongoing industry criticism, is a reminder to advertise responsibly.

Should pharma abandon social media?

Should pharma abandon social media?

Cultivating relationships digitally is a long-term play. Yet few pharma campaigns are set up for that kind of promotion

It's time for J&J to challenge the Credo...again

It's time for J&J to challenge the Credo...again

Will J&J ever regain its once stellar reputation for ethics and social responsibility?

Coffee over co-pay: How did it come to this?

Coffee over co-pay: How did it come to this?

Remember when it felt good to say you worked in pharma? How to get the people who benefit from our products to recognize and articulate the value they receive

Do depot drugs really deliver?

Do depot drugs really deliver?

In schizophrenia, non-compliance can be disastrous. Do depot drugs really make a difference for patients?

Is the current agency model a joke?

Is the current agency model a joke?

Why agencies must get out of the strategy business.

I'll take DTC for $10 million, Alex

I'll take DTC for $10 million, Alex

The Wizards of White Oak are spending $10 million on DTC ad research. Is this a wise use of sparse agency resources?

Which companies stand out post-ASCO?

Which companies stand out post-ASCO?

ASCO not only offered a peek at developing treatments likely to be commercialized. Its impact also put some companies in the limelight from a business-development perspective.

What NOT to tell an MS Patient

What NOT to tell an MS Patient

It is often hard to find the right words when talking to a patient, friend or family member with MS. Even with training and awareness of the disease, we often blurt out something we think is innocuous only to find out later that we have deeply offended. The Health Activists that Extrovertic spoke to had some suggestions for having positive conversations with someone with MS.

Angelina Jolie's flawed message

Angelina Jolie's flawed message

Angelina Jolie's story raises important questions about education, outreach and access—but her nod to holistic treatments is less helpful

It's Consumer's Choices as Guidelines Change

It's Consumer's Choices as Guidelines Change

Welcome to the ambivalent world of healthcare, where confusion reigns as shifts in science and guidelines seemingly raise more questions than they answer.

Novartis makes, the world takes

Novartis makes, the world takes

India, a nation known for its innovation in many areas, has decided that incremental innovation in pharmaceuticals isn't important—at least when it comes to patent protection

Ready for Healthcare Anywhere?

Ready for Healthcare Anywhere?

Healthcare is moving from its traditional two places for delivery—the hospital and the doctor's office—to the patient, aided in part by mobile devices and always-on connectivity.

The Snow Companies

The Snow Companies

OPUS Health

OPUS Health

The Oncologist

The Oncologist

Intouch Solutions

Intouch Solutions

ICC Lowe

ICC Lowe

Group DCA

Group DCA

Greater Than One

Greater Than One

Concentric

Concentric

BulletinHealthcare

BulletinHealthcare

10 trends that will change the face of the industry (if they haven't already)

10 trends that will change the face of the industry (if they haven't already)

Any pharma marketers who are guilty of ignoring, instead of embracing, the following themes, are already behind the curve. Larry Dobrow reports on 10 game-changing ideas in healthcare

Game Changers 2013

Game Changers 2013

In this special supplement to MM&M, we report on some of the trends that are changing (or are about to change) the face of the healthcare industry

Why SGLT-2s may put some spring into pharma spending

Why SGLT-2s may put some spring into pharma spending

Should the FDA give the thumbs-up to J&J diabetes pill Invokana tomorrow, expect a blockbuster US marketing push, says CSD's Jerry Maynor.

Coming face-to-face with advanced cancer

Coming face-to-face with advanced cancer

A relative's illness challenges a pharma consultant's view of industry progress.

AMARC Angst: Has FDA put pharma Facebook "Likes" in the crosshairs?

AMARC Angst: Has FDA put pharma Facebook "Likes" in the crosshairs?

What the agency writes in a recent warning letter to a dietary supplement firm is instructive with regard to "Liking" off-label posts.

DDR at the movies: "Side Effects"

DDR at the movies: "Side Effects"

When Hollywood shines its spotlight on your industry, you never know how you're going to be portrayed. In "Side Effects," the view is less than flattering.

Op/ed: A way for biopharma to disclose more trial data

Op/ed: A way for biopharma to disclose more trial data

At a time when some regulatory bodies and biopharma companies are increasing their transparency initiatives involving access to clinical-trial data, disclosing trial results to volunteers could also go a long way toward strengthening public confidence.

Op/Ed: Meningitis crisis and the threat to pharma

Op/Ed: Meningitis crisis and the threat to pharma

The deadly meningitis outbreak highlights the threat not only to public health, but also to the pharma industry, posed by the largely unregulated practice of pharmacy compounding.

Five industry experts advise specialty pharma company on digital strategy

Five industry experts advise specialty pharma company on digital strategy

Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.

WEB EXCLUSIVE: Pharmas must step up and lead on off-label, online communications

WEB EXCLUSIVE: Pharmas must step up and lead on off-label, online communications

FDA's recent draft guidance on off-label communication is, despite its shortcomings, a step forward, writes John Kamp, arguing that pharmas should take this welcome bit of clarity and act boldly on it

WEB EXCLUSIVE: FDA says "Pharma, guide thyself"

WEB EXCLUSIVE: FDA says "Pharma, guide thyself"

FDA's first draft guidance to come out of its 2009 online communication hearing offers sound counsel but not much in the way of specifics, writes Peter Pitts. The takeaway: where the letter of the law is hazy, exercise your judgement and follow, as best you can, the spirit of the law.

WEB EXCLUSIVE - Pragmatism vs. Possibility: the false pharma fight over the iPad

WEB EXCLUSIVE - Pragmatism vs. Possibility: the false pharma fight over the iPad

The pace of adoption of the iPad continues to startle, and already half of the top 20 pharma companies have bought into the tablet platform. But now comes the tricky part: how will pharma actually use their fancy new machines? Bill Drummy reports.

Email Newsletters